Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04326439 · ClinicalTrials.gov registry record · Phase 2
AflacLL1901 (CHOA-AML)
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04326439: Clinical Trial Phase 2 study, sponsored by Emory University.
NCT04326439 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04326439, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.
Primary Outcome
Event-free survival defined as the time from on study to death, failure to achieve remission or relapse in newly diagnosed patients with pediatric acute myeloid leukemia in the Low risk stratification group and High risk stratification group
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Gemtuzumab ozogamicin
- DRUG Erwinase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-01-24 |
| Est. Completion | 2022-03-15 |
| Phase | Phase 2 |
Why NCT04326439 stopped before completion
NCT04326439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Etoposide is the first listed.
NCT04326439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04326439 about?
NCT04326439 is a clinical study titled "AflacLL1901 (CHOA-AML)". The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.
What is the current status of trial NCT04326439?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-01-24. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT04326439?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), Gemtuzumab ozogamicin (DRUG), Erwinase (DRUG).
Who is sponsoring clinical trial NCT04326439?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04326439's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI